AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31210343 — intervention group
Group type: EXPERIMENTAL
Intervention: Saudi nutrition policy compliance
Number of subjects: 76
Study 31210343 — intervention group
Group type: EXPERIMENTAL
Intervention: Institute of Medicine (IOM) standards compliance
Number of subjects: 76
Study 28156185 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-release dimethyl fumarate (DMF)
Number of subjects: 200
Study 28156185 — intervention group
Group type: EXPERIMENTAL
Intervention: Monomethyl fumarate (MMF)
Number of subjects: 200
Study 28156185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 24698135 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT DVD + 12-week pedometer-based walking programme
Number of subjects: 59
Study 24698135 — intervention group
Group type: COMPARATOR
Intervention: Walking programme in isolation
Number of subjects: 59
Study 24379032 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 15
Study 24379032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 21793958 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive group (contingency management)
Number of subjects: 319
Study 21793958 — intervention group
Group type: COMPARATOR
Intervention: Control group (treatment-as-usual)
Number of subjects: 319
Study 19907854 — intervention group
Group type: EXPERIMENTAL
Intervention: METAPEX
Number of subjects: 178
Study 19907854 — intervention group
Group type: COMPARATOR
Intervention: Zinc oxide eugenol paste (control)
Number of subjects: 178
Study 17076067 — intervention group
Group type: EXPERIMENTAL
Intervention: Circle (small and large; no part structure)
Number of subjects: 0
Study 17076067 — intervention group
Group type: EXPERIMENTAL
Intervention: Bell (shape with two parts, one larger than the other)
Number of subjects: 0
Study 15347035 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (90 mg/day during 10 days)
Number of subjects: 43
Study 15347035 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (45 mg/day during 10 days)
Number of subjects: 43
Study 15347035 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 10 days)
Number of subjects: 43
Study 11320583 — intervention group
Group type: EXPERIMENTAL
Intervention: Videolaryngostroboscope
Number of subjects: 99
Study 11320583 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurements of vibration, amplitude, frequency and mucosal wave of vocal cords
Number of subjects: 99
Study 9146782 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsules with enteric-coated microtablets (2 capsules, 40,000 U lipase and 2000 proteases)
Number of subjects: 20
Study 9146782 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated tablets (3 tablets, 40,000 U lipase and 2000 proteases)
Number of subjects: 20
Study 9146782 — intervention group
Group type: COMPARATOR
Intervention: Control (no enzymes, n = 20)
Number of subjects: 20
Study 9146782 — intervention group
Group type: COMPARATOR
Intervention: Control (no enzymes)
Number of subjects: 20
Study 7970446 — intervention group
Group type: EXPERIMENTAL
Intervention: Toshiba GCA-9300A SPET system with lead fanbeam super high-resolution collimators (SHR FB) for 99Tcm-HMPAO brain SPET studies
Number of subjects: 0
Study 7970446 — intervention group
Group type: EXPERIMENTAL
Intervention: Toshiba GCA-9300A SPET system with high-resolution parallel-hole collimators (HR PH) for cardiac and other body studies
Number of subjects: 0
Study 2890021 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg)
Number of subjects: 16
Study 2890021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31900080 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (50,000 IU fortnightly) + Calcium (500 mg daily)
Number of subjects: 81
Study 31900080 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (50,000 IU fortnightly) + Calcium placebo
Number of subjects: 81
Study 31900080 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Vitamin D and Calcium)
Number of subjects: 81
Study 28918652 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster aspart
Number of subjects: 37
Study 28918652 — intervention group
Group type: COMPARATOR
Intervention: Insulin aspart
Number of subjects: 37
Study 27225739 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg lornoxicam (Group L)
Number of subjects: 60
Study 27225739 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg paracetamol (Group P)
Number of subjects: 60
Study 27225739 — intervention group
Group type: COMPARATOR
Intervention: Saline (Group C)
Number of subjects: 60
Study 24458173 — intervention group
Group type: EXPERIMENTAL
Intervention: Red ginseng anti-hangover drink (RGD)
Number of subjects: 25
Study 24458173 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100 mL water)
Number of subjects: 25
Study 23782587 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg vildagliptin twice daily co-administered with 0.2 mg voglibose three times daily
Number of subjects: 24
Study 23782587 — intervention group
Group type: COMPARATOR
Intervention: 50 mg vildagliptin twice daily
Number of subjects: 24
Study 21083918 — intervention group
Group type: EXPERIMENTAL
Intervention: bio-psycho-social chronic back pain specific aftercare intervention (RÜCKGEWINN)
Number of subjects: 456
Study 21083918 — intervention group
Group type: EXPERIMENTAL
Intervention: usual aftercare (IRENA)
Number of subjects: 456
Study 21083918 — intervention group
Group type: COMPARATOR
Intervention: educational booklet addressing pain-conditioned functional ability and back pain episodes
Number of subjects: 456
Study 18230277 — intervention group
Group type: EXPERIMENTAL
Intervention: High-monounsaturated fatty acid (MUFA) enteral formula
Number of subjects: 22
Study 18230277 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate enteral formula
Number of subjects: 22
Study 16767422 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan (1 g 3x a day)
Number of subjects: 38
Study 16767422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 14531252 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 10 mg
Number of subjects: 0
Study 14531252 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 12.5 mg
Number of subjects: 0
Study 14531252 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 15 mg
Number of subjects: 0
Study 14531252 — intervention group
Group type: COMPARATOR
Intervention: Tetracaine 10 mg
Number of subjects: 0
Study 10979796 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg daily
Number of subjects: 241
Study 10979796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 241
Study 9002808 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji Cap II
Number of subjects: 83
Study 9002808 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji II LC
Number of subjects: 83
Study 9002808 — intervention group
Group type: EXPERIMENTAL
Intervention: APH/Universal Bond 3
Number of subjects: 83
Study 9002808 — intervention group
Group type: EXPERIMENTAL
Intervention: Lite Fil II A/Imperva Bond
Number of subjects: 83
Study 1480768 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionation (HF) of 80.5 Gy in 70 fractions in 7 weeks using 2 fractions of 1.15 Gy per day
Number of subjects: 356
Study 1480768 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation (CF) of 70 Gy in 35-40 fractions in 7-8 weeks
Number of subjects: 356
Study 1480768 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HF and CF
Number of subjects: 356
Study 1480768 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionation (HF)
Number of subjects: 356
Study 453496 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate (0.25 mg/kg)
Number of subjects: 50
Study 453496 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate (intravenous injection)
Number of subjects: 50
Study 31162585 — intervention group
Group type: EXPERIMENTAL
Intervention: HAW breads (high-amylose wheat)
Number of subjects: 20
Study 31162585 — intervention group
Group type: COMPARATOR
Intervention: LAW breads (low-amylose wheat)
Number of subjects: 20
Study 28735463 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg/day)
Number of subjects: 42
Study 28735463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 28735463 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 42
Study 26480555 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal acupuncture
Number of subjects: 90
Study 26480555 — intervention group
Group type: COMPARATOR
Intervention: Auricular point
Number of subjects: 90
Study 23921780 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 0
Study 23921780 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Lifestyle Counseling (BLC)
Number of subjects: 0
Study 23921780 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Brief Lifestyle Counseling (EBLC)
Number of subjects: 0
Study 22153012 — intervention group
Group type: EXPERIMENTAL
Intervention: Xingnaojing (20 ml/d i.v. drip) + L-carnitine (2 g/d i.v. drip)
Number of subjects: 69
Study 22153012 — intervention group
Group type: COMPARATOR
Intervention: Xingnaojing (20 ml/d i.v. drip)
Number of subjects: 69
Study 19826292 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual ergogenic spray containing vitamins, minerals, amino acids, and a coenzyme
Number of subjects: 23
Study 19826292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 17101639 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy care program (standardized medication education, regular follow-up by pharmacists, medications dispensed in time-specific packs)
Number of subjects: 200
Study 17101639 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy care program
Number of subjects: 200
Study 17101639 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study 17101639 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy care
Number of subjects: 200
Study 16169367 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate juice (240 ml/day)
Number of subjects: 45
Study 16169367 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage (similar caloric content, amount, flavor, and color)
Number of subjects: 45
Study 12945828 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (20 g creatine monohydrate for 5 days)
Number of subjects: 16
Study 12945828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 10085546 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-model problem with the crucial premise in the last position
Number of subjects: 0
Study 10085546 — intervention group
Group type: COMPARATOR
Intervention: Two-model problem with the crucial premise in the first position
Number of subjects: 0
Study 7891248 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional manual probe
Number of subjects: 15
Study 7891248 — intervention group
Group type: COMPARATOR
Intervention: Automated force-controlled electronic probe
Number of subjects: 15
Study 2236581 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 90 mg administered orally in divided doses for 12 weeks
Number of subjects: 178
Study 2236581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study 380963 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (Amuno, Indocid)
Number of subjects: 100
Study 380963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 31369124 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous genetic scores
Number of subjects: 0
Study 31369124 — intervention group
Group type: COMPARATOR
Intervention: 2×2 approach
Number of subjects: 0
Study 29484638 — intervention group
Group type: EXPERIMENTAL
Intervention: GDC-0853 (≤600 mg, single ascending dose; ≤250 mg twice daily; ≤500 mg once daily for 14 days)
Number of subjects: 0
Study 29484638 — intervention group
Group type: EXPERIMENTAL
Intervention: GDC-0853
Number of subjects: 0
Study 29484638 — intervention group
Group type: EXPERIMENTAL
Intervention: GDC-0853 (100 mg, once daily)
Number of subjects: 0
Study 28827417 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg rifampin
Number of subjects: 150
Study 28827417 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg rifampin
Number of subjects: 150
Study 28827417 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,200 mg rifampin
Number of subjects: 150
Study 28827417 — intervention group
Group type: COMPARATOR
Intervention: rifampin (600 mg, 900 mg, 1,200 mg)
Number of subjects: 150
Study 23757100 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal prevention measures in kindergarten setting
Number of subjects: 0
Study 23757100 — intervention group
Group type: COMPARATOR
Intervention: Selective prevention measures in kindergarten setting
Number of subjects: 0
Study 23904465 — intervention group
Group type: EXPERIMENTAL
Intervention: BPA exposure (20, 200 ng/ml or 20 µg/ml)
Number of subjects: 121
Study 21961465 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP Lifestyle program
Number of subjects: 228
Study 21961465 — intervention group
Group type: COMPARATOR
Intervention: Attention control intervention (cognitive training)
Number of subjects: 228
Study 20298323 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS (fluticasone propionate) + LABA (salmeterol) (500 mcg/50 mcg bd)
Number of subjects: 61
Study 20298323 — intervention group
Group type: COMPARATOR
Intervention: ICS alone (500 mcg bd)
Number of subjects: 61
Study 20298323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 20298323 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild symptoms group
Number of subjects: 61
Study 16176606 — intervention group
Group type: EXPERIMENTAL
Intervention: Soya foods (two daily servings including tofu, soya milk, soya nuts, and soya protein powder; equivalent to 50 mg isoflavones and 5-22 g soya protein per serving)
Number of subjects: 196
Study 16176606 — intervention group
Group type: COMPARATOR
Intervention: Control group (maintained regular diet)
Number of subjects: 196
Study 16176606 — intervention group
Group type: EXPERIMENTAL
Intervention: Soya foods
Number of subjects: 196
Study 12548322 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient induction with intravaginal controlled-release prostaglandin-E2 (CR-PGE2)
Number of subjects: 300
Study 12548322 — intervention group
Group type: COMPARATOR
Intervention: Inpatient induction with intravaginal controlled-release prostaglandin-E2 (CR-PGE2)
Number of subjects: 300
Study 10778689 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (0.25 mg/kg)
Number of subjects: 32
Study 10778689 — intervention group
Group type: COMPARATOR
Intervention: Esmolol (0.5 mg/kg)
Number of subjects: 32
Study 8903808 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective lead shield
Number of subjects: 20
Study 8903808 — intervention group
Group type: COMPARATOR
Intervention: No protective shield
Number of subjects: 20
Study 1846331 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg intravenous timolol
Number of subjects: 6
Study 1846331 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg quinidine pretreatment
Number of subjects: 6
Study 1846331 — intervention group
Group type: COMPARATOR
Intervention: Isoproterenol infusions
Number of subjects: 6
Study 7082538 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term oral cimetidine treatment
Number of subjects: 12
Study 29890239 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 40
Study 29890239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 27981688 — intervention group
Group type: EXPERIMENTAL
Intervention: CLARIFIG static
Number of subjects: 682
Study 27981688 — intervention group
Group type: COMPARATOR
Intervention: MFP static
Number of subjects: 682
Study 27981688 — intervention group
Group type: EXPERIMENTAL
Intervention: CLARIFIG animated
Number of subjects: 682
Study 27981688 — intervention group
Group type: COMPARATOR
Intervention: MFP animated
Number of subjects: 682
Study 26034240 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-targeted communication training
Number of subjects: 347
Study 26034240 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 347
Study 26034240 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician self-efficacy in communicating with parents
Number of subjects: 347
Study 24797376 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron sucrose 100 mg IV thrice weekly for up to 2 weeks
Number of subjects: 150
Study 24797376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 22278344 — intervention group
Group type: EXPERIMENTAL
Intervention: 84 mg soy germ isoflavones
Number of subjects: 90
Study 22278344 — intervention group
Group type: EXPERIMENTAL
Intervention: 126 mg soy germ isoflavones
Number of subjects: 90
Study 22278344 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg soy germ isoflavones)
Number of subjects: 90
Study 22278344 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups (84 mg, 126 mg, and placebo)
Number of subjects: 90
Study 19338655 — intervention group
Group type: COMPARATOR
Intervention: Patient safety program addressing pressure ulcers, falls, and urinary tract infections, implemented for fourteen months after a three-month baseline period and followed by a nine-month follow-up.
Number of subjects: 20
Study 19338655 — intervention group
Group type: COMPARATOR
Intervention: Patient safety program
Number of subjects: 20
Study 17602019 — intervention group
Group type: EXPERIMENTAL
Intervention: Family psychoeducation group program
Number of subjects: 84
Study 17602019 — intervention group
Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 84
Study 15293895 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg per day)
Number of subjects: 82
Study 15293895 — intervention group
Group type: COMPARATOR
Intervention: Control (no tibolone)
Number of subjects: 82
Study 11251483 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsutured
Number of subjects: 80
Study 11251483 — intervention group
Group type: COMPARATOR
Intervention: Sutured
Number of subjects: 80
Study 9307692 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning light therapy
Number of subjects: 12
Study 9307692 — intervention group
Group type: COMPARATOR
Intervention: Normal controls (no intervention)
Number of subjects: 12
Study 8316616 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic oral contraceptive (OC) for 3 months
Number of subjects: 45
Study 8316616 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 45
Study 8316616 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic oral contraceptive (OC)
Number of subjects: 45
Study 8316616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 3577356 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent split vaccine (15 micrograms haemagglutinin of A-H3N2, A-H1N1, and B strains)
Number of subjects: 101
Study 3577356 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster injection of the same vaccine dosage four weeks after the first immunization
Number of subjects: 101
Study 3577356 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 101
Study 30712326 — intervention group
Group type: EXPERIMENTAL
Intervention: Good psychiatric management treatment
Number of subjects: 37
Study 30712326 — intervention group
Group type: EXPERIMENTAL
Intervention: Good psychiatric management treatment with the addition of the Motive‐Oriented Therapeutic Relationship
Number of subjects: 37
Study 30712326 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 37
Study 30541217 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberine (0.4 g, 3 times a day)
Number of subjects: 114
Study 30541217 — intervention group
Group type: COMPARATOR
Intervention: Control group (only hypoglycemic agents)
Number of subjects: 114
Study 27998236 — intervention group
Group type: EXPERIMENTAL
Intervention: Seribantumab plus paclitaxel
Number of subjects: 223
Study 27998236 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel alone
Number of subjects: 223
Study 27998236 — intervention group
Group type: EXPERIMENTAL
Intervention: Seribantumab plus paclitaxel (in patients with detectable HRG mRNA and low HER2)
Number of subjects: 223
Study 27998236 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel alone (in patients with detectable HRG mRNA and low HER2)
Number of subjects: 223
Study 24742381 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth cognitive stimulation therapy (therapist-assisted) for 4 weeks, 2-3 days/week
Number of subjects: 68
Study 24742381 — intervention group
Group type: COMPARATOR
Intervention: Control (treatment-as-usual with no neuropsychological intervention)
Number of subjects: 68
Study 22212621 — intervention group
Group type: EXPERIMENTAL
Intervention: Attainment of KDOQI clinical performance targets
Number of subjects: 715
Study 22212621 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of performance targets reached
Number of subjects: 715
Study 20061884 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased availability of healthy items to 50% and price reductions of at least 10% in vending machines at two bus garages.
Number of subjects: 33
Study 20061884 — intervention group
Group type: COMPARATOR
Intervention: Control group with usual availability and prices in two bus garages.
Number of subjects: 33
Study 18227331 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive hand exercise for 5 min (exercise group)
Number of subjects: 40
Study 18227331 — intervention group
Group type: COMPARATOR
Intervention: Resting arms after ISB (nonexercise group)
Number of subjects: 40
Study 16164466 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum bite force during submerged healing
Number of subjects: 18
Study 16164466 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum bite force during functional loading
Number of subjects: 18
Study 16164466 — intervention group
Group type: COMPARATOR
Intervention: Sequence of attachment types (ball, magnet, bar-clip)
Number of subjects: 18
Study 12634966 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous transluminal coronary angioplasty (PTCA) in patients with angiographic no reflow (group 1)
Number of subjects: 117
Study 12634966 — intervention group
Group type: COMPARATOR
Intervention: Primary percutaneous transluminal coronary angioplasty (PTCA) in patients without angiographic no reflow (group 2)
Number of subjects: 117